
ABRAM SCIENTIFIC

Fast hemostasis information for improved outcomes
CoagCare Platform
01 / FAST
Less than 5-10 minutes
from insertion of sample (approx. 20 microliters) to
full viscoelastic curve and parameter generation
02 / PORTABLE
Low-cost, single-use diagnostic test strips that interface with a wireless, handheld meter that is vibration-insensitive
03 / ACCURATE
Mechanical viscoelasticity and density measurement for blood coagulation diagnostics

CoagCare / PLATFORM CAPABILITIES*
-
Thromboelastography
-
Clot Formation Time
-
Clot Stiffness (Fibrinogen)
-
Platelet Activity
-
Fibrinolysis
-
-
Thrombin Generation Assay
-
Direct Oral Anticoagulants (DOAC) Monitoring (including Factor IIa and Xa drug differentiation)
-
Prothrombin Time (PT) / International Normalized Ratio (INR)
-
Hematocrit (Hct)
-
Activated Partial Thromboplastin Time (aPTT)
-
Low- and High-range Activated Clotting Time (ACT)
* feasibility demonstrated on clinical & analytical blood samples
COVID-19
Coagulopathy is a major cause of death in COVID-19 patients
-
A high incidence of thromboembolic complications leading to organ-failure, stroke, pulmonary embolism (PE) and deep vein thrombosis (DVT) have been reported in asymptomatic, symptomatic, and recovering patient groups.
-
Coagulopathy plays a crucial role in the initial development of respiratory symptoms in COVID-19 patients and monitoring could predict disease progression.
-
Anticoagulation and transfusion therapies and monitoring are crucially needed both in inpatient and outpatient settings to ensure survival.
Viscoelastic tests can accurately detect and manage Coagulopathy
-
Consensus guidelines published by physicians and surgeons from the pandemic frontline in Wuhan specifically recommends the routine use of viscoelastic tests for diagnosing the type and extent of coagulopathy in COVID-19 patients.
-
Viscoelastic tests are increasingly being used as the ideal go-to-solution to screen for and accurately diagnose the hypercoagulable state observed in COVID-19 patients (i.e. by measuring clot stiffness & lysis) and enable goal-directed anticoagulation and blood transfusion management.
Critical need for fast, point-of-care (POC) viscoelastic tests to:
-
Quickly screen for coagulopathy in asymptomatic and symptomatic COVID-19 patients.
-
Provide closed-loop therapeutic management in ambulatory, inpatient and outpatient settings.
Abram Scientific is engaging with frontline physicians at leading ER and trauma centers to address this critical need using the CoagCare platform.
NEWS
Abram Scientific Secures $1 Million National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase II Grant (Click for Details)